Evaxion Reports Sustained Three-Year Clinical Responses for Personalized Cancer Vaccine EVX-01 in Advanced Melanoma

Evaxion A/S has announced new three-year clinical outcome data from its Phase 2 trial of the personalized cancer vaccine EVX-01 in patients with advanced melanoma. All patients at the three-year follow-up maintained the clinical responses observed at two years, with no tumor progression. In the third year, patients received EVX-01 as a stand-alone therapy, further supporting the long-term durability of clinical responses in this difficult-to-treat patient population.